Avid Bioservices Inc has a consensus price target of $12.5 based on the ratings of 5 analysts. The high is $16 issued by Craig-Hallum on December 8, 2023. The low is $8 issued by RBC Capital on July 3, 2024. The 3 most-recent analyst ratings were released by RBC Capital, RBC Capital, and Stephens & Co. on July 3, 2024, April 30, 2024, and March 11, 2024, respectively. With an average price target of $9.33 between RBC Capital, RBC Capital, and Stephens & Co., there's an implied -13.26% downside for Avid Bioservices Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/03/2024 | Buy Now | -25.65% | RBC Capital | Sean Dodge | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
04/30/2024 | Buy Now | -25.65% | RBC Capital | Sean Dodge | $7 → $8 | Maintains | Outperform | Get Alert |
03/11/2024 | Buy Now | 11.52% | Stephens & Co. | Jacob Johnson | $15 → $12 | Maintains | Overweight | Get Alert |
03/07/2024 | Buy Now | -34.94% | RBC Capital | Sean Dodge | → $7 | Reiterates | Outperform → Outperform | Get Alert |
12/08/2023 | Buy Now | -34.94% | RBC Capital | Sean Dodge | $15 → $7 | Maintains | Outperform | Get Alert |
12/08/2023 | Buy Now | 48.7% | Craig-Hallum | Matt Hewitt | $22 → $16 | Maintains | Buy | Get Alert |
12/08/2023 | Buy Now | 30.11% | Keybanc | Paul Knight | $20 → $14 | Maintains | Overweight | Get Alert |
09/28/2023 | Buy Now | — | William Blair | Max Smock | — | Initiates | → Market Perform | Get Alert |
09/08/2023 | Buy Now | 39.41% | RBC Capital | Sean Dodge | $17 → $15 | Maintains | Outperform | Get Alert |
06/22/2023 | Buy Now | 57.99% | RBC Capital | Sean Dodge | $20 → $17 | Maintains | Outperform | Get Alert |
06/22/2023 | Buy Now | 85.87% | Stephens & Co. | Jacob Johnson | → $24 | Reiterates | Overweight → Overweight | Get Alert |
03/14/2023 | Buy Now | 104.46% | Stephens & Co. | Jacob Johnson | → $22 | Reiterates | → Overweight | Get Alert |
03/14/2023 | Buy Now | 85.87% | RBC Capital | Sean Dodge | → $20 | Reiterates | → Outperform | Get Alert |
03/14/2023 | Buy Now | 85.87% | Keybanc | Paul Knight | → $20 | Upgrade | Sector Weight → Overweight | Get Alert |
12/07/2022 | Buy Now | 85.87% | RBC Capital | Sean Dodge | $22 → $20 | Maintains | Outperform | Get Alert |
06/30/2022 | Buy Now | 104.46% | RBC Capital | Sean Dodge | $32 → $22 | Maintains | Outperform | Get Alert |
03/09/2022 | Buy Now | 160.22% | Stephens & Co. | Jacob Johnson | $31 → $28 | Maintains | Overweight | Get Alert |
12/08/2021 | Buy Now | 225.28% | Craig-Hallum | Matt Hewitt | — | Maintains | Buy | Get Alert |
12/08/2021 | Buy Now | 197.4% | RBC Capital | Sean Dodge | — | Maintains | Outperform | Get Alert |
12/08/2021 | Buy Now | — | Keybanc | Paul Knight | — | Downgrade | Overweight → Sector Weight | Get Alert |
The latest price target for Avid Bioservices (NASDAQ:CDMO) was reported by RBC Capital on July 3, 2024. The analyst firm set a price target for $8.00 expecting CDMO to fall to within 12 months (a possible -25.65% downside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Avid Bioservices (NASDAQ:CDMO) was provided by RBC Capital, and Avid Bioservices reiterated their outperform rating.
The last upgrade for Avid Bioservices Inc happened on March 14, 2023 when Keybanc raised their price target to $20. Keybanc previously had a sector weight for Avid Bioservices Inc.
The last downgrade for Avid Bioservices Inc happened on December 8, 2021 when Keybanc changed their price target from N/A to N/A for Avid Bioservices Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avid Bioservices, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avid Bioservices was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
While ratings are subjective and will change, the latest Avid Bioservices (CDMO) rating was a reiterated with a price target of $8.00 to $8.00. The current price Avid Bioservices (CDMO) is trading at is $10.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.